坦桑尼亚恶性疟原虫对青蒿素耐药性的分子监测
Molecular monitoring of Plasmodium falciparum resistance to artemisinin in Tanzania.
作者信息
Mugittu Kefas, Genton Blaise, Mshinda Hassan, Beck Hans Peter
机构信息
Ifakara Health Research and Development Centre, Ifakara, Tanzania.
出版信息
Malar J. 2006 Dec 19;5:126. doi: 10.1186/1475-2875-5-126.
Abstract
Artemisinin-based combination therapies (ACTs) are recommended for use against uncomplicated malaria in areas of multi-drug resistant malaria, such as sub-Saharan Africa. However, their long-term usefulness in these high transmission areas remains unclear. It has been suggested that documentation of the S769N PfATPase6 mutations may indicate an emergence of artemisinin resistance of Plasmodium falciparum in the field. The present study assessed PfATPase6 mutations (S769N and A623E) in 615 asymptomatic P. falciparum infections in Tanzania but no mutant genotype was detected. This observation suggests that resistance to artemisinin has not yet been selected in Tanzania, supporting the Ministry of Health's decision to adopt artemether+lumefantrine as first-line malaria treatment. The findings recommend further studies to assess PfATPase6 mutations in sentinel sites and verify their usefulness in monitoring emergency of ACT resistance.
摘要
以青蒿素为基础的联合疗法（ACTs）被推荐用于治疗撒哈拉以南非洲等多药耐药疟疾地区的非复杂性疟疾。然而，它们在这些高传播地区的长期有效性仍不明确。有人提出，记录S769N PfATPase6突变可能表明恶性疟原虫在野外出现了对青蒿素的耐药性。本研究评估了坦桑尼亚615例无症状恶性疟原虫感染中的PfATPase6突变（S769N和A623E），但未检测到突变基因型。这一观察结果表明，坦桑尼亚尚未出现对青蒿素的耐药性，支持了卫生部将蒿甲醚+本芴醇作为一线疟疾治疗药物的决定。研究结果建议进一步开展研究，以评估哨点地区的PfATPase6突变，并验证其在监测ACT耐药性出现方面的作用。
相似文献
1
Molecular monitoring of Plasmodium falciparum resistance to artemisinin in Tanzania.
Malar J. 2006 Dec 19;5:126. doi: 10.1186/1475-2875-5-126.
2
No PfATPase6 S769N mutation found in Plasmodium falciparum isolates from China.
Malar J. 2008 Jul 8;7:122. doi: 10.1186/1475-2875-7-122.
3
Prevalence of potential mediators of artemisinin resistance in African isolates of Plasmodium falciparum.
Malar J. 2021 Dec 2;20(1):451. doi: 10.1186/s12936-021-03987-6.
4
Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6.
Lancet. 2005 Dec 3;366(9501):1960-3. doi: 10.1016/S0140-6736(05)67787-2.
5
Plasmodium falciparum from Pará state (Brazil) shows satisfactory in vitro response to artemisinin derivatives and absence of the S769N mutation in the SERCA-type PfATPase6.
Trop Med Int Health. 2008 Feb;13(2):199-207. doi: 10.1111/j.1365-3156.2007.01991.x.
6
Monitoring artemisinin resistance in Plasmodium falciparum: comparison of parasite clearance time by microscopy and real-time PCR and evaluation of mutations in Pfatpase6 gene in Odisha state of India.
Parasitol Res. 2015 Sep;114(9):3487-96. doi: 10.1007/s00436-015-4577-x. Epub 2015 Jun 27.
7
Detection of point mutation in Plasmodium falciparum ATPase6 gene associated with artemisinin resistance from Assam and Arunachal Pradesh.
J Vector Borne Dis. 2014 Dec;51(4):282-5.
8
Geographic expansion of artemisinin resistance.
J Travel Med. 2019 Jun 1;26(4). doi: 10.1093/jtm/taz030.
9
Absence of kelch13 artemisinin resistance markers but strong selection for lumefantrine-tolerance molecular markers following 18 years of artemisinin-based combination therapy use in Mpumalanga Province, South Africa (2001-2018).
Malar J. 2019 Aug 22;18(1):280. doi: 10.1186/s12936-019-2911-y.
10
In vitro assessment of artesunate, artemether and amodiaquine susceptibility and molecular analysis of putative resistance-associated mutations of Plasmodium falciparum from São Tomé and Príncipe.
Trop Med Int Health. 2007 Mar;12(3):353-62. doi: 10.1111/j.1365-3156.2006.01789.x.
引用本文的文献
1
Efficacy of artesunate-amodiaquine for treatment of uncomplicated Plasmodium falciparum malaria in mainland Tanzania.
Malar J. 2024 Mar 29;23(1):90. doi: 10.1186/s12936-024-04923-0.
2
Antimalarial Drug Predictions Using Molecular Descriptors and Machine Learning against Plasmodium Falciparum.
Biomolecules. 2021 Nov 24;11(12):1750. doi: 10.3390/biom11121750.
3
Alkaloids from Plants with Antimalarial Activity: A Review of Recent Studies.
Evid Based Complement Alternat Med. 2020 Feb 12;2020:8749083. doi: 10.1155/2020/8749083. eCollection 2020.
4
Molecular surveillance of putative drug resistance markers of antifolate and artemisinin among imported in Qatar.
Pathog Glob Health. 2019 Jun;113(4):158-166. doi: 10.1080/20477724.2019.1639018. Epub 2019 Jul 12.
5
Predictors of residual antimalarial drugs in the blood in community surveys in Tanzania.
PLoS One. 2018 Sep 7;13(9):e0202745. doi: 10.1371/journal.pone.0202745. eCollection 2018.
6
Molecular markers of anti-malarial drug resistance in Central, West and East African children with severe malaria.
Malar J. 2017 May 23;16(1):217. doi: 10.1186/s12936-017-1868-y.
7
Limited artemisinin resistance-associated polymorphisms in Plasmodium falciparum K13-propeller and PfATPase6 gene isolated from Bioko Island, Equatorial Guinea.
Int J Parasitol Drugs Drug Resist. 2016 Jan 12;6(1):54-59. doi: 10.1016/j.ijpddr.2015.11.002. eCollection 2016 Apr.
8
High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania.
Malar J. 2015 Nov 5;14:439. doi: 10.1186/s12936-015-0977-8.
9
Monitoring artemisinin resistance in Plasmodium falciparum: comparison of parasite clearance time by microscopy and real-time PCR and evaluation of mutations in Pfatpase6 gene in Odisha state of India.
Parasitol Res. 2015 Sep;114(9):3487-96. doi: 10.1007/s00436-015-4577-x. Epub 2015 Jun 27.
10
Occurrence of pfatpase6 Single Nucleotide Polymorphisms Associated with Artemisinin Resistance among Field Isolates of Plasmodium falciparum in North-Eastern Tanzania.
Malar Res Treat. 2015;2015:279028. doi: 10.1155/2015/279028. Epub 2015 Jan 5.
本文引用的文献
1
Putting the genie back in the bottle? Availability and presentation of oral artemisinin compounds at retail pharmacies in urban Dar-es-Salaam.
Malar J. 2006 Mar 29;5:25. doi: 10.1186/1475-2875-5-25.
2
Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10.
Antimicrob Agents Chemother. 2006 Feb;50(2):480-9. doi: 10.1128/AAC.50.2.480-489.2006.
3
Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6.
Lancet. 2005 Dec 3;366(9501):1960-3. doi: 10.1016/S0140-6736(05)67787-2.
4
Are we losing artemisinin combination therapy already?
Lancet. 2005 Dec 3;366(9501):1908-9. doi: 10.1016/S0140-6736(05)67768-9.
5
A single amino acid residue can determine the sensitivity of SERCAs to artemisinins.
Nat Struct Mol Biol. 2005 Jul;12(7):628-9. doi: 10.1038/nsmb947. Epub 2005 Jun 5.
6
Contribution of the pfmdr1 gene to antimalarial drug-resistance.
Acta Trop. 2005 Jun;94(3):181-90. doi: 10.1016/j.actatropica.2005.04.008.
7
Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria.
Trans R Soc Trop Med Hyg. 2005 Jun;99(6):459-67. doi: 10.1016/j.trstmh.2004.09.013.
8
Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.
Am J Trop Med Hyg. 2004 Dec;71(6):696-702.
9
History, dynamics, and public health importance of malaria parasite resistance.
Clin Microbiol Rev. 2004 Jan;17(1):235-54. doi: 10.1128/CMR.17.1.235-254.2004.
10
The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy.
Trop Med Int Health. 2003 Oct;8(10):860-7. doi: 10.1046/j.1360-2276.2003.01114.x.
Zotero 插件